The involvement of kallikrein-kinin system in diabetes type I (insulitis).
Islet inflammation or insulitis is followed by selective destruction of the insulin secreting B-cell. Animal models of insulin-dependent diabetes mellitus (IDDM) have been used to characterize more fully insulitis, and our results with C57/BL/Ks mdb with low doses of streptozotocin (STZ) confirmed the disease. B1 receptor antagonist [Leu8]des-Arg9-BK has shown a significant effect on diabetic glycemia and renal control parameters. Compared to insulin, the drug was effective to prevent the insulitis and the renal damage. On the other hand, B2 receptor antagonist (HOE 140) and ACE-I (captopril) were only able to control the urinary diabetic proteinuria.
Zuccollo
A
A
PROSIVAD-CONICET, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina.
Navarro
M
M
Frontera
M
M
Cueva
F
F
Carattino
M
M
Catanzaro
O L
OL
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000378:metabolism; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D065168:Bradykinin Receptor Antagonists; D003922:Diabetes Mellitus, Type 1 / Q000378:metabolism* / Q000473:pathology; D007515:Islets of Langerhans / Q000378:metabolism* / Q000473:pathology; D016234:Kallikrein-Kinin System / Q000502:physiology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D011507:Proteinuria / Q000188:drug therapy / Q000378:metabolism; D011897:Random Allocation; D043783:Receptor, Bradykinin B1; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin / Q000627:therapeutic use
D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D065168:Bradykinin Receptor Antagonists; D043783:Receptor, Bradykinin B1; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin